The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy

Int J Clin Pharmacol Ther. 2003 Dec;41(12):610-1. doi: 10.5414/cpp41610.

Authors

W Jäger¹, E Gehring, B Hagenauer, S Aust, A Senderowicz, T Thalhammer

Affiliation

¹ Institute of Pharmaceutical Chemistry, University of Vienna, Austria.

PMID: 14692715
DOI: 10.5414/cpp41610

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

ATP-Binding Cassette Transporters*
Animals
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / metabolism
Antineoplastic Agents / pharmacokinetics*
Carrier Proteins / pharmacology*
Disease Models, Animal
Drug Interactions
Flavonoids / adverse effects*
Flavonoids / metabolism
Flavonoids / pharmacokinetics*
Hyperbilirubinemia / chemically induced*
Hyperbilirubinemia / physiopathology
Male
Piperidines / adverse effects*
Piperidines / metabolism
Piperidines / pharmacokinetics*
Rats
Rats, Wistar

Substances

ATP-Binding Cassette Transporters
Abcc2 protein, rat
Antineoplastic Agents
Carrier Proteins
Flavonoids
Piperidines
alvocidib